MedWatch

Questions about Demant's future remain as 2022 nears

Market shares have been won, and the company is ending 2021 with a bigger foothold and a better bottom line than when the year began. While the smoke of the corona crisis dissipates, uncertainty remains for 2022 forecasts, and the future at large.

Photo: Demant / PR

One could be forgiven for thinking that Demant is a stable and perhaps even slightly boring company in which to invest.

The hearing aid marketplace, where the firm does its business, is relatively easy to predict. Added to this is the fact that the industry is dominated by a few, big players, competing among themselves to have the best products with the latest technology on the market – but they treat each other gently when it comes to pricing.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs